I’m an independent researcher in Austin, TX
working on cross-national pharmacovigilance
for GLP-1 receptor agonists. My infrastructure
harmonizes multiple national adverse event
databases in OMOP CDM v5.4.
I have a manuscript currently in review at a
Springer Nature journal and several additional
papers in progress.
Looking for:
Pharmacoepidemiologists with OMOP experience
Researchers with access to additional national
pharmacovigilance databases
Clinicians in gastroenterology or endocrinology
Statisticians familiar with disproportionality
methods
Happy to discuss scope and share details directly
with interested collaborators.
This topic is of a huge relevance not only for gastroentorologists/endocrinologists, but also to anesthesiologists due to potential risks of aspiration during induction.
I will be happy to collaborate as a clinician/ help with general OMOP guidance with focus on vocabulary work.
Interesting work. There aren’t many groups trying to bring pharmacovigilance data from different countries into a common OMOP framework, so it’s great to see someone working in this space.
One thing I’ve often wondered is how you’re handling the differences in reporting practices and coding across databases. Even after mapping everything to OMOP, those differences can still influence signal detection results, especially when using disproportionality methods.
I also think there’s a real opportunity to combine this kind of standardized data with automation in pharmacovigilance. As more routine case processing and data harmonization become automated, it opens up possibilities for more efficient signal detection and signal validation, while still keeping scientific review at the center of the process.
With the increasing use of GLP-1 receptor agonists, it’ll be interesting to see how safety signals evolve as larger and more diverse datasets become available. Looking forward to reading your published work, and I hope the collaboration goes well.